Interventional Oncology Market by Product (Radiofrequency, microwave, cryoablation, embolization, guidewires), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis) - Global Forecast to 2024

インターベンショナルオンコロジーの世界市場予測(~2024年)

◆タイトル:Interventional Oncology Market by Product (Radiofrequency, microwave, cryoablation, embolization, guidewires), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis) - Global Forecast to 2024
◆商品コード:MD-6975
◆調査・発行会社:MarketsandMarkets
◆発行日:2019年3月25日
◆ページ数:181
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥604,550見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥711,550見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥872,050見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

インターベンショナルオンコロジーとは、がんの診断、治療、または緩和ケアのために用いられる低侵襲的手段を意味します。インターベンショナルオンコロジーの世界市場は、2019年の20億米ドルから2024年には29億米ドルに達し、この期間中6.8%の年平均成長率で成長すると予測されています。この市場の成長を促す要因として、低侵襲的手段への選好の高まり、対象患者人口の拡大、官民の資金援助やがん研究に対する政府の支援、インターベンショナルオンコロジー分野における技術的進歩、そしてインターベンショナルオンコロジーと関連するがんの研究に対する政府の投資と支援の増加が考えられます。一方で、十分に熟練した放射線科医や腫瘍医の不足、低侵襲的手術の高コスト、そして不利な規制により、市場の成長は抑制されると予測されます。当調査レポートでは、インターベンショナルオンコロジーの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、産業動向、市場シェア分析、製品(高周波、マイクロ波、冷凍アブレーション、塞栓術、ガイドワイヤー)分析、処置(サーマルアブレーション、非サーマルアブレーション、TACE、TARE、TAE)分析、がん(肝臓、肺、腎臓、がんの骨転移)分析、インターベンショナルオンコロジーの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

“The global interventional oncology market is projected to grow at a CAGR of 6.8% during the forecast period”Interventional oncology refers to the use of minimally invasive procedures performed for the diagnosis, treatment, or palliative care of cancer. The global interventional oncology market is projected to reach USD 2.9 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 6.8% from 2019 to 2024. The growth of this market is primarily driven by the rising preference for minimally invasive procedures, expansion of the target patient population, increasing public-private funding and government support for cancer research, technological advancements in the field of interventional oncology, and increasing government investments and funding for interventional oncology and related cancer research. However, the dearth of well-trained and skilled radiologists and oncologists, high costs of interventional oncology procedures, and unfavorable regulations are expected to limit market growth to a certain extent.

“The transcatheter arterial radioembolization TARE or selective internal radiation therapy SIRT segment accounted for the largest share of the global interventional oncology market during the forecast period”
On the basis of procedure, the interventional oncology market is segmented into thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization TACE, transcatheter arterial radioembolization TARE or selective internal radiation therapy SIRT, and transcatheter arterial embolization TAE or bland embolization procedures. In 2018, the TARE/SIRT procedures segment accounted for the largest share of this market majorly due to the rising prevalence of cancer, increasing demand for minimally invasive procedures, growing adoption of embolization procedures, and the clinical efficacy of Yttrium-90 radioembolic agents which are used in these procedures.

“The liver cancer segment accounted for the largest share of the interventional oncology market during the forecast period”
Based on cancer type, the interventional oncology market is segmented into liver cancer, lung cancer, kidney cancer, bone cancer, and other cancers. The other cancers segment includes pediatric cancer, prostate cancer, and breast cancer. The liver cancer segment accounted for the largest share in the interventional oncology market in 2018.

“Europe accounted for the second-largest share of the global market in 2018”
The interventional oncology market is segmented into five major regions, namely North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Europe accounted for the second-largest share in 2018. The rising incidence of cancer, coupled with the growing geriatric population in Europe, is a key factor propelling the demand for interventional oncology products in this region. Prominent market players are focusing on improving the quality of patient care across Europe by commercializing advanced products, investing in technological innovations, and partnering with other institutions and organizations for spreading cancer awareness. This is another major factor driving market growth.

Breakdown of supply-side primary interviews:
• By Company Type: Tier 1 – 25%, Tier 2 – 30%, and Tier 3 – 45%
• By Designation: C-level – 26%, Director-level – 30%, and Others – 44%
• By Region: North America – 34%, Europe – 26%, APAC – 23%, and RoW – 17%

The major players in the market include Medtronic Ireland, Boston Scientific US, BTG plc UK, Merit Medical Systems US, and Terumo Japan. The other prominent players operating in the overall interventional oncology market include AngioDynamics US, Ethicon a part of J&J US, Teleflex US, Cook Medical US, HealthTronics US, MedWaves Medical US, Sanarus US, IMBiotechnologies Canada, Trod Medical US, IceCure Medical Israel, Mermaid Medicals Denmark, and Interface Biomaterials BV Netherlands, among others.

Research Coverage
This report studies the interventional oncology market based on products, procedure, cancer type, and region. The report also studies factors such as drivers, restraints, opportunities, and challenges affecting market growth. It also provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions and the respective countries in these regions.

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market shares of top players, and company profiles, which together form basic views. It also analyzes the competitive landscape; emerging segments of the interventional oncology market; and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED FOR THE STUDY 22
1.4 CURRENCY 22
1.5 STAKEHOLDERS 22
2 RESEARCH METHODOLOGY 23
2.1 RESEARCH DATA 23
2.1.1 SECONDARY DATA 25
2.1.1.1 Key data from secondary sources 25
2.1.2 PRIMARY DATA 26
2.1.2.1 Key data from primary sources 27
2.2 MARKET SIZE ESTIMATION 29
2.2.1 PRODUCT-BASED MARKET ESTIMATION 29
2.2.2 PRIMARY RESEARCH VALIDATION 30
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 31
2.4 RESEARCH LIMITATIONS AND ASSUMPTIONS 32
2.4.1 LIMITATIONS 32
2.4.2 ASSUMPTIONS 32
3 EXECUTIVE SUMMARY 33
4 PREMIUM INSIGHTS 36
4.1 INTERVENTIONAL ONCOLOGY: MARKET OVERVIEW 36
4.2 GEOGRAPHIC ANALYSIS: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT 37
4.3 ASIA PACIFIC: ABLATION DEVICES MARKET, BY TYPE (2018) 38
4.4 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE (2018) 39
4.5 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019 VS. 2024 (USD MILLION) 40
4.6 GEOGRAPHICAL SNAPSHOT OF THE INTERVENTIONAL ONCOLOGY MARKET 41

5 MARKET OVERVIEW 42
5.1 INTRODUCTION 42
5.2 MARKET DYNAMICS 42
5.2.1 DRIVERS 43
5.2.1.1 Rising patient preference for minimally invasive procedures 43
5.2.1.2 Expansion of the target patient population 43
5.2.1.3 Increasing public-private funding and government support for interventional oncology 44
5.2.1.4 Technological advancements in interventional oncology 44
5.2.2 RESTRAINTS 45
5.2.2.1 Dearth of well-trained and skilled radiologists and oncologists 45
5.2.2.2 Unfavorable regulations 45
5.2.3 OPPORTUNITIES 46
5.2.3.1 Emerging economies offer high growth potential 46
5.2.3.2 Rising awareness about the benefits of interventional oncology 46
5.2.4 CHALLENGES 47
5.2.4.1 Limited clinical data to support therapeutic efficacy 47
5.2.4.2 Strong market positioning of alternative therapies 47
5.3 MARKET TRENDS 47
5.3.1 PERSONALIZED OR PRECISION INTERVENTIONAL ONCOLOGY 47
6 INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT 48
6.1 INTRODUCTION 49
6.2 EMBOLIZATION DEVICES 49
6.2.1 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET SPLIT,
BY PROCEDURE 51
6.2.2 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET SPLIT,
BY CANCER TYPE 52
6.2.3 RADIOEMBOLIC AGENTS 52
6.2.3.1 Radioembolic agents dominated the interventional oncology embolization devices market in 2018 52
6.2.3.1.1 Radioembolic agents market split, by procedure 53
6.2.3.1.2 Radioembolic agents market split, by cancer type 54
6.2.4 NON-RADIOACTIVE EMBOLIC AGENTS 54
6.2.4.1 Embolization procedures cannot be used to treat cancers in advanced stages, which is a major factor restraining market growth 54
6.2.4.1.1 Non-radioactive embolic agents market split, by procedure 56
6.2.4.1.2 Non-radioactive embolic agents market split, by cancer type 57
6.3 ABLATION DEVICES 57
6.3.1 TECHNOLOGICAL ADVANCEMENTS IN ABLATION DEVICES—A KEY DRIVER FOR MARKET GROWTH 57
6.3.1.1 Interventional oncology ablation devices market split, by procedure 59
6.3.1.2 Interventional oncology ablation devices market split, by cancer type 59
6.3.2 RADIOFREQUENCY (RF) ABLATION DEVICES 60
6.3.2.1 Growing competition among different technologies offered by key players, backed by long-term clinical efficacy data, to drive the RF ablation devices market 60
6.3.2.1.1 Radiofrequency ablation devices market split, by procedure 61
6.3.2.1.2 Radiofrequency ablation devices market split, by cancer type 62
6.3.3 MICROWAVE ABLATION DEVICES 62
6.3.3.1 Microwave ablation enables the simultaneous treatment of multiple lesions—A key factor driving market growth 62
6.3.3.1.1 Microwave ablation devices market split, by procedure 63
6.3.3.1.2 Microwave ablation devices market split, by cancer type 63
6.3.4 CRYOABLATION DEVICES 64
6.3.4.1 Advantages of cryoablation over other thermal ablation techniques to drive market growth in the coming years 64
6.3.4.1.1 Cryoablation devices market split, by procedure 65
6.3.4.1.2 Cryoablation devices market split, by cancer type 65
6.3.5 OTHER ABLATION DEVICES 65
6.3.5.1 Other ablation devices market split, by procedure 66
6.3.5.2 Other ablation devices market split, by cancer type 67
6.4 SUPPORT DEVICES 67
6.4.1 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET SPLIT,
BY PROCEDURE 68
6.4.2 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET SPLIT,
BY CANCER TYPE 69
6.4.3 MICROCATHETERS 69
6.4.3.1 Regulatory approvals driving the growth of the microcatheters market 69
6.4.3.1.1 Microcatheters market split, by procedure 70
6.4.3.1.2 Microcatheters market split, by cancer type 70
6.4.4 GUIDEWIRES 71
6.4.4.1 Advancements in guidewire construction and the launch of new and advanced products are the major factors driving the growth of this market 71
6.4.4.1.1 Guidewires market split, by procedure 71
6.4.4.1.2 Guidewires market split, by cancer type 72
7 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE 73
7.1 INTRODUCTION 74
7.2 THERMAL TUMOR ABLATION 75
7.2.1 INCREASING CLINICAL EVIDENCE IS A MAJOR FACTOR DRIVING MARKET GROWTH 75
7.3 NON-THERMAL TUMOR ABLATION 76
7.3.1 NANOKNIFE HAS EMERGED AS A POTENTIAL ALTERNATIVE TO THERMAL TUMOR ABLATION TECHNIQUES 76

7.4 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION 77
7.4.1 ABILITY TO TREAT SMALL AND LARGE-SIZED TUMORS – A MAJOR FACTOR DRIVING THE DEMAND FOR TACE PROCEDURES 77
7.5 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY 79
7.5.1 TARE SHOWS GREATER CLINICAL EFFICACY AS COMPARED TO TACE 79
7.6 TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION 80
7.6.1 INCREASING CLINICAL EVIDENCE FOR TARE AND TACE TO RESTRAIN GROWTH OF THIS MARKET 80
8 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE 82
8.1 INTRODUCTION 83
8.1.1 LIVER CANCER 84
8.1.1.1 Increasing disease prevalence and rising research activity are driving market growth 84
8.1.2 LUNG CANCER 85
8.1.2.1 Increasing number of cancer cases will drive the demand for interventional oncology procedures 85
8.1.3 BONE CANCER 86
8.1.3.1 Interventional oncology procedures can eliminate tumors directly and relieve pain 86
8.1.4 KIDNEY CANCER 87
8.1.4.1 Interventional oncology procedures are appropriate for patients with a genetic disposition for multiple tumors 87
8.1.5 OTHER CANCERS 88
9 INTERVENTIONAL ONCOLOGY MARKET, BY REGION 89
9.1 INTRODUCTION 90
9.2 NORTH AMERICA 92
9.2.1 US 96
9.2.1.1 US to dominate the North American interventional oncology market 96
9.2.2 CANADA 98
9.2.2.1 Public-private initiatives to support the adoption of interventional oncology procedures in Canada 98
9.3 EUROPE 100
9.3.1 GERMANY 103
9.3.1.1 Germany is the fastest-growing market in Europe 103
9.3.2 UK 105
9.3.2.1 Increasing awareness and support for cancer-related activities to drive market growth in the UK 105
9.3.3 FRANCE 107
9.3.3.1 Radiofrequency ablation dominated the ablation devices market in France 107
9.3.4 REST OF EUROPE 109

9.4 ASIA PACIFIC 112
9.4.1 JAPAN 116
9.4.1.1 Rising geriatric population and universal healthcare reimbursement are the major driving factors 116
9.4.2 CHINA 118
9.4.2.1 Increasing cancer incidence and growing patient population to drive market growth in China 118
9.4.3 INDIA 120
9.4.3.1 Improving research capabilities coupled with the expansion of key players to drive market growth in India 120
9.4.4 REST OF ASIA PACIFIC 122
9.5 LATIN AMERICA 124
9.5.1 BRAZIL 127
9.5.1.1 Brazil to account for the largest share of the Latin American interventional oncology market 127
9.5.2 MEXICO 129
9.5.2.1 Growing awareness campaigns and rising incidence of cancer to drive market growth in Mexico 129
9.5.3 REST OF LATIN AMERICA 132
9.6 MIDDLE EAST AND AFRICA 134
9.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND RISING INCIDENCE OF CANCER ARE DRIVING GROWTH IN THE MIDDLE EAST AND AFRICA 134
10 COMPETITIVE LANDSCAPE 137
10.1 OVERVIEW 137
10.2 GLOBAL MARKET SHARE ANALYSIS, 2017 138
10.3 COMPETITIVE SCENARIO (2015 – 2019) 139
10.3.1 KEY PRODUCT LAUNCHES 139
10.3.2 KEY ACQUISITIONS 139
10.3.3 KEY AGREEMENTS AND COLLABORATIONS 140
10.4 VENDOR DIVE OVERVIEW 140
10.5 VENDOR INCLUSION CRITERIA 140
10.6 VENDOR DIVE 140
10.6.1 VANGUARDS 140
10.6.2 INNOVATORS 141
10.6.3 DYNAMIC DIFFERENTIATORS 141
10.6.4 EMERGING COMPANIES 141

11 COMPANY PROFILES 142
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
11.1 HEALTHTRONICS, INC. 142
11.2 TROD MEDICAL 144
11.3 SANARUS TECHNOLOGIES, INC. 145
11.4 TELEFLEX, INC. 146
11.5 IMBIOTECHNOLOGIES LTD. 148
11.6 MEDWAVES, INC. 149
11.7 ICECURE MEDICAL 150
11.8 TERUMO CORPORATION 151
11.9 MEDTRONIC PLC 154
11.10 BTG PLC 158
11.11 JOHNSON & JOHNSON 161
11.12 MERIT MEDICAL SYSTEMS, INC. 163
11.13 BOSTON SCIENTIFIC CORPORATION 166
11.14 ANGIODYNAMICS, INC. 169
11.15 COOK MEDICAL 171

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
12 APPENDIX 172
12.1 DISCUSSION GUIDE 172
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 177
12.3 AVAILABLE CUSTOMIZATIONS 179
12.4 RELATED REPORTS 179
12.5 AUTHOR DETAILS 180

LIST OF TABLES

TABLE 1 INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 49
TABLE 2 RECENT PRODUCT LAUNCHES AND APPROVALS OF EMBOLIZATION DEVICES 50
TABLE 3 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 50
TABLE 4 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY REGION, 2017–2024 (USD MILLION) 51
TABLE 5 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY PROCEDURE, 2017–2024 (USD MILLION) 51
TABLE 6 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY CANCER TYPE, 2017–2024 (USD MILLION) 52
TABLE 7 RADIOEMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS 52
TABLE 8 RADIOEMBOLIC AGENTS MARKET, BY REGION, 2017–2024 (USD MILLION) 53
TABLE 9 RADIOEMBOLIC AGENTS MARKET, BY PROCEDURE, 2017–2024 (USD MILLION) 53
TABLE 10 RADIOEMBOLIC AGENTS MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION) 54
TABLE 11 NON-RADIOACTIVE EMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS 55
TABLE 12 NON-RADIOACTIVE EMBOLIC AGENTS MARKET, BY REGION,
2017–2024 (USD MILLION) 56
TABLE 13 NON-RADIOACTIVE EMBOLIC AGENTS MARKET, BY PROCEDURE,
2017–2024 (USD MILLION) 56
TABLE 14 NON-RADIOACTIVE EMBOLIC AGENTS MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 57
TABLE 15 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 58
TABLE 16 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY REGION,
2017–2024 (USD MILLION) 58
TABLE 17 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY PROCEDURE, 2017–2024 (USD MILLION) 59
TABLE 18 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION) 59
TABLE 19 RADIOFREQUENCY ABLATION DEVICES OFFERED BY MAJOR MARKET PLAYERS 60
TABLE 20 RADIOFREQUENCY ABLATION DEVICES MARKET, BY REGION,
2017–2024 (USD MILLION) 61
TABLE 21 RADIOFREQUENCY ABLATION DEVICES MARKET, BY PROCEDURE,
2017–2024 (USD MILLION) 61
TABLE 22 RADIOFREQUENCY ABLATION DEVICES MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 62
TABLE 23 MICROWAVE ABLATION DEVICES MARKET, BY REGION, 2017–2024 (USD MILLION) 63
TABLE 24 MICROWAVE ABLATION DEVICES MARKET, BY PROCEDURE,
2017–2024 (USD MILLION) 63
TABLE 25 MICROWAVE ABLATION DEVICES MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 63
TABLE 26 CRYOABLATION DEVICES MARKET, BY REGION, 2017–2024 (USD MILLION) 64
TABLE 27 CRYOABLATION DEVICES MARKET, BY PROCEDURE, 2017–2024 (USD MILLION) 65
TABLE 28 CRYOABLATION DEVICES MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION) 65
TABLE 29 OTHER ABLATION DEVICES MARKET, BY REGION, 2017–2024 (USD MILLION) 66
TABLE 30 OTHER ABLATION DEVICES MARKET, BY PROCEDURE, 2017–2024 (USD MILLION) 66
TABLE 31 OTHER ABLATION DEVICES MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 67
TABLE 32 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 67
TABLE 33 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY REGION,
2017–2024 (USD MILLION) 68
TABLE 34 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY PROCEDURE, 2017–2024 (USD MILLION) 68
TABLE 35 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION) 69
TABLE 36 MICROCATHETERS MARKET, BY REGION, 2017–2024 (USD MILLION) 69
TABLE 37 MICROCATHETERS MARKET, BY PROCEDURE, 2017–2024 (USD MILLION) 70
TABLE 38 MICROCATHETERS MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION) 70
TABLE 39 GUIDEWIRES MARKET, BY REGION, 2017–2024 (USD MILLION) 71
TABLE 40 GUIDEWIRES MARKET, BY PROCEDURE, 2017–2024 (USD MILLION) 71
TABLE 41 GUIDEWIRES MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION) 72
TABLE 42 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,
2017–2024 (USD MILLION) 74
TABLE 43 THERMAL TUMOR ABLATION PROCEDURES MARKET, BY REGION,
2017–2024 (USD MILLION) 76
TABLE 44 NON-THERMAL TUMOR ABLATION PROCEDURES MARKET, BY REGION,
2017–2024 (USD MILLION) 77
TABLE 45 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION PROCEDURES MARKET,
BY REGION, 2017–2024 (USD MILLION) 78
TABLE 46 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY PROCEDURES MARKET, BY REGION,
2017–2024 (USD MILLION) 80
TABLE 47 TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION PROCEDURES MARKET, BY REGION, 2017–2024 (USD MILLION) 81
TABLE 48 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 83
TABLE 49 INTERVENTIONAL ONCOLOGY MARKET FOR LIVER CANCER,
BY REGION, 2017–2024 (USD MILLION) 84
TABLE 50 INTERVENTIONAL ONCOLOGY MARKET FOR LUNG CANCER,
BY REGION, 2017–2024 (USD MILLION) 85
TABLE 51 INTERVENTIONAL ONCOLOGY MARKET FOR BONE CANCER,
BY REGION, 2017–2024 (USD MILLION) 86
TABLE 52 INTERVENTIONAL ONCOLOGY MARKET FOR KIDNEY CANCER,
BY REGION, 2017–2024 (USD MILLION) 87
TABLE 53 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER CANCERS,
BY REGION, 2017–2024 (USD MILLION) 88
TABLE 54 INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2017–2024 (USD MILLION) 91
TABLE 55 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 93
TABLE 56 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 93
TABLE 57 NORTH AMERICA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 93
TABLE 58 NORTH AMERICA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 94
TABLE 59 NORTH AMERICA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 94
TABLE 60 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,
2017–2024 (USD MILLION) 95
TABLE 61 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 95
TABLE 62 US: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 96
TABLE 63 US: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 97
TABLE 64 US: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 97
TABLE 65 US: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 97
TABLE 66 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 98
TABLE 67 CANADA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 99
TABLE 68 CANADA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 99
TABLE 69 CANADA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 99
TABLE 70 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 100
TABLE 71 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 101
TABLE 72 EUROPE: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 101
TABLE 73 EUROPE: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 101
TABLE 74 EUROPE: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 102
TABLE 75 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,
2017–2024 (USD MILLION) 102
TABLE 76 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 103
TABLE 77 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 104
TABLE 78 GERMANY: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 104
TABLE 79 GERMANY: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 104
TABLE 80 GERMANY: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 105
TABLE 81 UK: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 106
TABLE 82 UK: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 106
TABLE 83 UK: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 107
TABLE 84 UK: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 107
TABLE 85 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 108
TABLE 86 FRANCE: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 108
TABLE 87 FRANCE: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 109
TABLE 88 FRANCE: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 109
TABLE 89 ROE: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 110
TABLE 90 ROE: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 110
TABLE 91 ROE: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 111
TABLE 92 ROE: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 111
TABLE 93 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 113
TABLE 94 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 113
TABLE 95 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 114
TABLE 96 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 114
TABLE 97 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 114
TABLE 98 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,
2017–2024 (USD MILLION) 115
TABLE 99 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 115
TABLE 100 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 116
TABLE 101 JAPAN: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 117
TABLE 102 JAPAN: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 117
TABLE 103 JAPAN: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 117
TABLE 104 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 119
TABLE 105 CHINA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 119
TABLE 106 CHINA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 119
TABLE 107 CHINA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 120
TABLE 108 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 121
TABLE 109 INDIA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 121
TABLE 110 INDIA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 121
TABLE 111 INDIA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 122
TABLE 112 ROAPAC: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 123
TABLE 113 ROAPAC: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 123
TABLE 114 ROAPAC: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 123
TABLE 115 ROAPAC: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 124
TABLE 116 LATAM: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 124
TABLE 117 LATAM: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 125
TABLE 118 LATAM: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 125
TABLE 119 LATAM: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 126
TABLE 120 LATAM: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 126
TABLE 121 LATAM: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,
2017–2024 (USD MILLION) 126
TABLE 122 LATAM: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 127
TABLE 123 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 128
TABLE 124 BRAZIL: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 128
TABLE 125 BRAZIL: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 128
TABLE 126 BRAZIL: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 129
TABLE 127 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 130
TABLE 128 MEXICO: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 130
TABLE 129 MEXICO: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 131
TABLE 130 MEXICO: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 131
TABLE 131 ROLA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 132
TABLE 132 ROLA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 132
TABLE 133 ROLA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 133
TABLE 134 ROLA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 133
TABLE 135 MEA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 134
TABLE 136 MEA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 135
TABLE 137 MEA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 135
TABLE 138 MEA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 135
TABLE 139 MEA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,
2017–2024 (USD MILLION) 136
TABLE 140 MEA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 136


LIST OF FIGURES

FIGURE 1 INTERVENTIONAL ONCOLOGY MARKET: RESEARCH METHODOLOGY STEPS 23
FIGURE 2 RESEARCH DESIGN 24
FIGURE 3 BREAKDOWN OF PRIMARIES: GLOBAL INTERVENTIONAL ONCOLOGY MARKET 28
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 28
FIGURE 5 BOTTOM-UP APPROACH MARKET SIZE ESTIMATION: INTERVENTIONAL ONCOLOGY MARKET 29
FIGURE 6 TOP-DOWN APPROACH MARKET SIZE ESTIMATION: INTERVENTIONAL ONCOLOGY MARKET 30
FIGURE 7 DATA TRIANGULATION METHODOLOGY 31
FIGURE 8 INTERVENTIONAL ONCOLOGY MARKET SHARE, BY PRODUCT, 2018 33
FIGURE 9 INTERVENTIONAL ONCOLOGY MARKET SHARE, BY PROCEDURE, 2018 34
FIGURE 10 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,
2019 VS. 2024 (USD MILLION) 34
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE INTERVENTIONAL ONCOLOGY MARKET 35
FIGURE 12 RISING PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES IS DRIVING THE GROWTH OF THE INTERVENTIONAL ONCOLOGY MARKET 36
FIGURE 13 ABLATION DEVICES SEGMENT TO WITNESS HIGH GROWTH IN THE MARKET DURING THE FORECAST PERIOD 37
FIGURE 14 RADIOFREQUENCY ABLATION SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC ABLATION DEVICES MARKET IN 2018 38
FIGURE 15 LIVER CANCER SEGMENT COMMANDED THE LARGEST SHARE OF THE EUROPEAN INTERVENTIONAL ONCOLOGY MARKET IN 2018 39
FIGURE 16 THERMAL TUMOR ABLATION SEGMENT TO WITNESS THE HIGHEST GROWTH IN THE FORECAST PERIOD 40
FIGURE 17 ASIA PACIFIC TO REGISTER THE HIGHEST CAGR IN THE INTERVENTIONAL ONCOLOGY MARKET DURING THE FORECAST PERIOD 41
FIGURE 18 INTERVENTIONAL ONCOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 42
FIGURE 19 LIVER CANCER SEGMENT TO DOMINATE THE INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, DURING THE FORECAST PERIOD 83
FIGURE 20 INTERVENTIONAL ONCOLOGY MARKET: GEOGRAPHIC SNAPSHOT 90
FIGURE 21 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT 92
FIGURE 22 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT 112
FIGURE 23 KEY DEVELOPMENTS IN THE INTERVENTIONAL ONCOLOGY MARKET
FROM 2015 TO 2019 137
FIGURE 24 MEDTRONIC HELD THE LEADING POSITION IN THE INTERVENTIONAL ONCOLOGY MARKET IN 2017 138
FIGURE 25 VENDOR DIVE: EVALUATION OVERVIEW 141
FIGURE 26 TELEFLEX: COMPANY SNAPSHOT 146
FIGURE 27 TERUMO CORPORATION: COMPANY SNAPSHOT 151
FIGURE 28 MEDTRONIC: COMPANY SNAPSHOT 154
FIGURE 29 BTG PLC: COMPANY SNAPSHOT 158
FIGURE 30 JOHNSON & JOHNSON: COMPANY SNAPSHOT 161

FIGURE 31 MERIT MEDICAL: COMPANY SNAPSHOT 163
FIGURE 32 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 166
FIGURE 33 ANGIODYNAMICS: COMPANY SNAPSHOT 169


★調査レポート[インターベンショナルオンコロジーの世界市場予測(~2024年)] ( Interventional Oncology Market by Product (Radiofrequency, microwave, cryoablation, embolization, guidewires), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis) - Global Forecast to 2024 / MD-6975) 販売に関する免責事項
[インターベンショナルオンコロジーの世界市場予測(~2024年)] ( Interventional Oncology Market by Product (Radiofrequency, microwave, cryoablation, embolization, guidewires), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis) - Global Forecast to 2024 / MD-6975) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆